RxSight (RXST) EBIT (2020 - 2026)

RxSight (RXST) has 7 years of EBIT data on file, last reported at -$17.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 67.03% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$55.4 million (down 50.17% YoY), and the FY2025 full-year result was -$48.2 million, down 30.77% from the prior year.
• EBIT for Q1 2026 stood at -$17.8 million, down from -$11.3 million in the prior quarter.
• Across five years, EBIT topped out at $34.3 million in Q4 2022 and bottomed at -$17.8 million in Q1 2026.
• The 5-year median for EBIT is -$12.2 million (2025), against an average of -$9.8 million.
• The widest annual swing landed in 2022, when EBIT jumped 334.0%; it then slumped 131.63% in 2023.
• A 5-year view of EBIT shows it stood at $34.3 million in 2022, then tumbled by 131.63% to -$10.9 million in 2023, then grew by 20.49% to -$8.6 million in 2024, then plunged by 31.5% to -$11.3 million in 2025, then plunged by 57.14% to -$17.8 million in 2026.
• The last three EBIT figures came in at -$17.8 million (Q1 2026), -$11.3 million (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.

Peer Comparison